Sudeep Pharma Ltd IPO: Check Subscription Status & Key Highlights


    Sudeep Pharma Ltd has opened its IPO for subscription, drawing strong attention from retail and NII investors today. The issue offers a mix of growth potential and sector stability, with early bidding trends providing a clear picture of investor sentiment. The IPO has already seen a 91.54x overall subscription, driven largely by non-institutional participation.

    In this blog, we break down the day-wise subscription numbers, investor category trends, IPO details, and utilisation of proceeds. You can also review more insights in the Sudeep Pharma Ltd IPO page for deeper understanding.

    Sudeep Pharma Ltd IPO Subscription Status

    Sudeep Pharma Ltd IPO recorded a 91.54x overall subscription today (as of Nov 24, 2025). Retail participation stood stable at 13.92x, while NII bids reached 114.89x, reflecting high demand from HNI investors. QIB (excluding anchor) participation boosted at 209.86x, which is typical today as institutional investors often bid closer to closing day.

    The momentum today suggests increasing traction across categories as the issue progresses.

    Subscription Table

    Investor Category

    Subscription (times)

    Shares Offered*

    Shares bid for

    Total Amount (Rs Cr.)*

    Anchor Investors

    1

    45,27,823

    45,27,823

    268.50

    QIB (Ex Anchor)

    209.86

    30,18,553

    63,34,79,050

    37,565.31

    Non-Institutional Buyers

    114.89

    22,63,912

    26,01,08,500

    15,424.43

    bNII (bids above ₹10L)

    134.12

    15,09,275

    20,24,28,025

    12,003.98

    sNII (bids below ₹10L)

    76.43

    7,54,637

    5,76,80,475

    3,420.45

    Retail Investors

    13.92

    52,82,462

    7,35,27,100

    4,360.16

    Total 

    91.54

    1,05,64,927

    96,71,14,650

    57,349.90

    Total Applications: 26,73,841 Calculated at upper price band.

    Sudeep Pharma Ltd – IPO Details

    Sudeep Pharma Ltd IPO is a public offering of 1.51 crore equity shares, structured to attract diverse investor participation. Retail investors have been allocated 0.53 crore shares, while QIBs receive the largest portion at 0.75 crore shares, making up 50% of the issue size. NII investors hold a 15% allocation, divided into sNII and bNII categories for varied bidding preferences.

    The IPO aims to support the company’s expansion plans and strengthen operational capabilities. With a total issue size of ₹895 crore, the offering positions Sudeep Pharma for its next phase of growth.

    Shares Offered Breakdown

    Category

    Shares Offered

    Amount (Rs Cr)

    Size (%)

    Anchor Investor

    45,27,823

    268.50

    30.00%

    QIB (Ex Anchor)

    75,46,376

    447.50

    50.00%

    NII

    22,63,912

    134.25

    15.00%

    bNII (bids above ₹10L)

    15,09,275

    89.50

    10.00%

    sNII (bids below ₹10L)

    7,54,637

    44.75

    5.00%

    Retail

    52,82,462

    313.25

    35.00%

    Total

    1,50,92,750

    895.00

    100%

    Utilisation of Proceeds

    • Funding expansion and capacity enhancement

    • Strengthening working capital requirements

    • Investment in R&D and process optimisation

    • General corporate purposes

    Sudeep Pharma Ltd IPO Anchor Investor Allocation

    Below is the anchor allocation structure as disclosed:

    Particulars

    Details

    Anchor Investor Bid Opening Date

    Nov 20, 2025

    Anchor Price

    ₹593.00 per share

    Total Shares Allotted

    45,27,823

    Allocation as % of QIB Portion

    Shares Locked for 30 Days

    0

    Shares Locked for 90 Days

    0

    Click here to check out recently closed IPO

    Conclusion

    The Sudeep Pharma Ltd IPO has begun on a positive note, especially with stable retail and NII participation shaping early demand. While QIB bids increased multifolds today, institutional activity often accelerates closer to closing, making the closing today important to watch.

    Overall, the IPO’s structure, anchor involvement, and subscription trends show stable market interest. Investors can track day-wise updates to understand how the bidding pattern evolves across categories.

    Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Sudeep Pharma Ltd IPO.

    Published Date : 25 Nov 2025

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |